Bifogade filer
Kurs
-1,87%
Likviditet
5,41 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-23 | 07:30 | Bokslutskommuniké 2026 |
| 2026-11-12 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-19 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-22 | N/A | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2026-05-21 | N/A | Årsstämma |
| 2026-05-20 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-19 | - | Bokslutskommuniké 2025 |
| 2025-11-13 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2025-05-15 | - | Årsstämma |
| 2025-05-14 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-19 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2023-05-17 | - | Årsstämma |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-08-16 | - | Extra Bolagsstämma 2021 |
| 2021-05-14 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2021-05-12 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-25 | - | Split SUS 1:5 |
| 2020-05-07 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-07-17 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-21 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-23 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
| 2018-05-22 | - | Årsstämma |
| 2018-05-22 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Invitation to attend Surgical Science's conference call regarding presentation of the Year-end report 2025. The presentation will be held in English.
Time: Thursday, February 19 at 11:00 a.m. CET.
If you wish to participate via webcast, please use the link below. It will be possible to ask written questions via the webcast.
https://surgical-science-sweden.events.inderes.com/q4-report-2025
If you wish to participate via teleconference, please register via the link below. After registration, you will receive phone numbers and a conference ID to access the conference. It will be possible to ask oral questions via the telephone conference.
https://events.inderes.com/surgical-science-sweden/q4-report-2025/dial-in
Participants from Surgical Science are:
Tom Englund, CEO
Anna Ahlberg, CFO
A press release with Surgical Science's Year-end report for 2025 will be published on February 19, 2026 at 07:30 a.m. CET.
Prior to the start of the conference call, presentation material will be available on the company's website, under Investors, Presentations.
Gothenburg, Sweden, February 9, 2026
Surgical Science Sweden AB (publ)
The press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Tom Englund, CEO
Telephone: +46-70-916 16 81
E-mail: tom.englund@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
Surgical Science is a global leader in evidence-based medical simulation. The company’s virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room - enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge.
Surgical Science has approximately 310 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB.